Stock report · Delisted · Nasdaq
Cara Therapeutic (CARA)
18.25USD Delisted Final close · Apr 16, 2025
CARA no longer trades. Cara Therapeutic was delisted from the Nasdaq in April 2025.
All prices on this page are historical. The last trade was on April 16, 2025, at $18.25.
CARA stock price history
Final trading statistics
- Final close
- $18.25
- Final trading day
- Apr 16, 2025
- Market cap at delisting
- $8.11M
- Shares outstanding
- 1.52M
- Final 52-week range
- $0.23 – $25.53
- Avg. volume (final 3 mo.)
- 24,987
- All-time high
- $1050.84 · Apr 2021
- All-time low
- $8.73 · Jun 2024
- Return since IPO
- -96.0%
- Beta
- 0.41
- Book value / share
- −$3.01
- Price / book
- -6.05
About Cara Therapeutic
Cara Therapeutics was a U.S. biopharmaceutical company focused on treating chronic itch (pruritus). Its main product was KORSUVA (difelikefalin) injection for moderate-to-severe itch tied to chronic kidney disease in adults on hemodialysis. An oral form of difelikefalin was in a Phase II/III trial for itch linked to notalgia paresthetica.
It licensed difelikefalin to Maruishi Pharmaceutical in Japan, to Vifor Fresenius Medical Care Renal Pharma for KORSUVA injection, and to Chong Kun Dang Pharmaceutical in South Korea. The company was incorporated in 2004 and based in Stamford, Connecticut.
Its shares were delisted from the Nasdaq in April 2025, with the last trade on April 16, 2025 at $18.25.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Stamford, CT
- Employees
- 10
- IPO date
- January 31, 2014
- Delisted
- April 16, 2025
- SEC CIK
- 1346830
Cara Therapeutic financials before the delisting
The last 5 fiscal years Cara Therapeutic reported as a public company, fiscal year ending December.
CARA revenue and net income
CARA earnings per share
CARA annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $7.14M | −$70.9M | −$2.73 |
| FY2023 | $20.97M | −$118.5M | −$2.18 |
| FY2022 | $41.87M | −$83.4M | −$1.59 |
| FY2021 | $23.03M | −$88.2M | −$1.73 |
| FY2020 | $135.08M | $8.4M | $0.08 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Cara Therapeutic stock FAQ
What happened to Cara Therapeutic stock?
Cara Therapeutic was delisted from the Nasdaq in April 2025. The final close was $18.25 on April 16, 2025.
Can I still buy CARA stock?
No. CARA is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on April 16, 2025.
What was the last price of CARA?
CARA last closed at $18.25 on April 16, 2025, which valued the company at about $8.11M.
How did Cara Therapeutic do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Cara Therapeutic reported revenue of $7.14M and net income of −$70.9M.
When did Cara Therapeutic go public?
Cara Therapeutic shares started trading on January 31, 2014.
CARA no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.